
The Australian Competition & Consumer Commission (ACCC) raised concerns Thursday, September 9, about Turnitin’s proposed acquisition of Ouriginal. Turnitin first announced its intent to acquire Ouriginal in March 2021.
Turnitin and Ouriginal are anti-plagiarism software vendors that largely provide their services to higher education consumers, such as educational institutions. They are two of only three companies that supply such software to Australian universities.
ACCC Commissioner Stephen Ridgeley said, “Ouriginal, which is a large supplier in Europe, has far fewer customers in Australia than Turnitin. However, it is one of Turnitin’s only competitors in the higher education sector and may develop into an important competitive constraint on Turnitin.”
The ACCC said in its statement of issues that the proposed acquisition may significantly diminish competition in the anti-plagiarism software market, resulting in increased prices. Furthermore, the ACC is concerned that the proposed acquisition would result in a reduction in worldwide innovation, which will lead to lower product innovation and quality for the Australian higher education segment. Notably, the UK Competition and Markets Authority approved Turnitin’s proposed acquisition in July.
While the ACCC is evaluating if other international software companies may enter and/or expand within Australia to compete with Turnitin, it is concerned about the barriers to such entry. The ACCC has invited submission from all the stakeholders concerned and it intends to take a final decision by November.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas